Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Announces Corporate Update and Reports First Quarter 2020 Financial Results
- Ongoing clinical programs remain on track with data readouts expected between 2020-21 - Progressing first- or best-in-class drug candidates with liquidity position of ~$1bn as of March 31, 2020 SAN DIEGO , May 7, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc.
View HTML
Toggle Summary Arena Pharmaceuticals to Release First Quarter 2020 Financial Results and Provide Corporate Update on May 7
SAN DIEGO , April 30, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2020 financial results and provide a corporate update on Thursday, May 7, 2020 , after the close of the U.S. financial markets. The Company will host a question and answer session
View HTML
Toggle Summary Arena Announces Management and Program Updates and Reports Fourth Quarter and Full-Year 2019 Financial Results
- Appoints Kevin R. Lind as President and Chief Executive Officer of Arena Neuroscience, Inc. - Appoints Laurie D. Stelzer as Executive Vice President and Chief Financial Officer of Arena - Expects to deliver up to eight major data readouts between 2020-21 and multiple INDs - Progressing first- or
View HTML
Toggle Summary Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2019 Financial Results and Provide Corporate Update on February 26
SAN DIEGO , Feb. 19, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its fourth quarter and full-year 2019 financial results and provide a corporate update on Wednesday, February 26, 2020 , after the close of the U.S. financial markets.
View HTML
Toggle Summary Arena Reports Third Quarter Financial Results with Continued Progress on Clinical Programs
- Etrasimod initiation of the Phase 2 ADVISE trial in atopic dermatitis (AD) - Multiple first- or best-in-class drug candidates, skilled leadership team and liquidity position of approximately $1.2 billion SAN DIEGO , Nov. 7, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc.
View HTML
Toggle Summary Arena Pharmaceuticals to Release Third Quarter 2019 Financial Results and Provide Corporate Update on November 7
SAN DIEGO , Oct. 31, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2019 financial results and provide a corporate update on Thursday, November 7, 2019 , after the close of the U.S. financial markets. The Company will host a conference call and live
View HTML
Toggle Summary Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Initiation of Etrasimod ELEVATE UC 52 and Olorinab CAPTIVATE Trials
- Etrasimod initiation of the Phase 3 ELEVATE UC 52 global trial in ulcerative colitis (UC) - Olorinab initiation of the Phase 2 CAPTIVATE clinical trial in abdominal pain associated with irritable bowel syndrome (IBS) - Multiple first- or best-in-class drug candidates, skilled leadership team and
View HTML
Toggle Summary Arena Pharmaceuticals to Release Second Quarter 2019 Financial Results and Provide Corporate Update on August 7
SAN DIEGO , July 31, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2019 financial results and provide a corporate update on Wednesday, August 7, 2019 , after the close of the U.S. financial markets. The Company will host a conference call and live
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2019 Financial Results
- Etrasimod ELEVATE UC Phase 3 Program expected to initiate mid-year targeting significant unmet need in ulcerative colitis - Multiple first- or best-in-class therapeutics, strong leadership team and liquidity position of approximately $1.3 billion SAN DIEGO , May 8, 2019 /PRNewswire/ -- Arena
View HTML
Toggle Summary Arena Pharmaceuticals to Release First Quarter 2019 Financial Results and Provide Corporate Update on May 8
SAN DIEGO , May 1, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2019 financial results and provide a corporate update on Wednesday, May 8, 2019 , after the close of the U.S. financial markets. The Company will host a conference call and live
View HTML